Design, Synthesis and Biological Evaluation of Novel Diaminopyrimidine Derivatives as Covalent Fibroblast Growth Factor Receptor 4 Inhibitors

[1]  Yaxin Li,et al.  Computational Investigations of Coumarin Derivatives as Cyclin-Dependent Kinase 9 Inhibitors Using 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation. , 2022, Current computer-aided drug design.

[2]  Jian Liu,et al.  Discovery of 1,6-Naphthyridin-2(1H)-one Derivatives as Novel, Potent, and Selective FGFR4 Inhibitors for the Treatment of Hepatocellular Carcinoma. , 2022, Journal of medicinal chemistry.

[3]  Liyang Shi,et al.  Discovery of Novel 7-Azaindole Derivatives as Selective Covalent Fibroblast Growth Factor Receptor 4 Inhibitors for the Treatment of Hepatocellular Carcinoma. , 2022, Journal of medicinal chemistry.

[4]  A. Unciti-Broceta,et al.  Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. , 2021, Journal of medicinal chemistry.

[5]  J. Smaill,et al.  Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors. , 2021, ACS medicinal chemistry letters.

[6]  W. Jahnke,et al.  Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4. , 2020, Journal of medicinal chemistry.

[7]  J. Smaill,et al.  Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. , 2020, Journal of medicinal chemistry.

[8]  Dengshuai Wei,et al.  Discovery of Dioxino[2,3-f]quinazoline derivative VEGFR-2 inhibitors exerting significant antipro-liferative activity in HUVECs and mice. , 2019, European journal of medicinal chemistry.

[9]  Qiang Zhang,et al.  Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2. , 2019, Bioorganic chemistry.

[10]  J. Smaill,et al.  Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. , 2018, Journal of medicinal chemistry.

[11]  N. Gray,et al.  Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.

[12]  Yong Xu,et al.  2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. , 2017, ACS medicinal chemistry letters.

[13]  P. Ross,et al.  Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma , 2015, Diseases.

[14]  H. Nakagama,et al.  FGF Receptors: Cancer Biology and Therapeutics , 2014, Medicinal research reviews.

[15]  D. French,et al.  Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models , 2012, PloS one.

[16]  Pascal Furet,et al.  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. , 2011, Journal of medicinal chemistry.

[17]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[18]  S. Kliewer,et al.  Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members , 2007, Molecular and Cellular Biology.

[19]  T. Kang,et al.  Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations. , 2014, Drug discovery today.